Table 3.

Prospective randomized and nonrandomized trials of all-trans retinoic acid (ATRA) and chemotherapy in acute promyelocytic leukemia (APL).43 

TrialNInduction% CR% ED% ED due to hemorrhage% DFS/EFS
Abbreviations: CR, complete remission; ED, early death; DFS, disease-free survival; EFS, event-free survival 
APL91 (Europe)35  54 ATRA + Chemo 97 9 60 79 
 47 Chemo 81 8 75 50 
APL93 (Europe)37  109 ATRA → Chemo 95 8  75 
 99 ATRA + Chemo 94 7 32 86 
North American Intergroup38  172 ATRA 72 11 56 67 
 174 Chemo 69 14 50 32 
TrialNInduction% CR% ED% ED due to hemorrhage% DFS/EFS
Abbreviations: CR, complete remission; ED, early death; DFS, disease-free survival; EFS, event-free survival 
APL91 (Europe)35  54 ATRA + Chemo 97 9 60 79 
 47 Chemo 81 8 75 50 
APL93 (Europe)37  109 ATRA → Chemo 95 8  75 
 99 ATRA + Chemo 94 7 32 86 
North American Intergroup38  172 ATRA 72 11 56 67 
 174 Chemo 69 14 50 32 
View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal